Skip to content
value.today

Promentis Pharmaceuticals, Inc.

Total raised
$31 M
4 rounds on record
Latest round
$3 M
Dec 2019
First round on record
Aug 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Promentis Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2019$3 MNo. 4$2 to $10 million

Promentis Pharmaceuticals, Inc.: Raise no. 4, Dec 2019

Investors in this round

8 investors had bought by the notice of Dec 27, 2019: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $6 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chad Beyer · Executive Officer
  • Daniel Lawton · Executive Officer, Director
  • Klaus Veitinger · Director
  • Patrick Schwarz-Schuette · Director
  • Stacey Seltzer · Director
  • Steve Squinto · Director
  • Thomas Beck · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds are used for research and development and general corporate purposes. The executive officers and certain directors will receive compensation from the Issuer's investment proceeds.”

Signed by Daniel Lawton, President. Newest notice filed Dec 27, 2019. Read the notice at the SEC.

debt, optionsSEC
Sep 2017$18 MNo. 3$10 to $50 million

Promentis Pharmaceuticals, Inc.: Raise no. 3, Sep 2017

Investors in this round

8 investors had bought by the notice of Sep 25, 2017: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chad Beyer · Executive Officer
  • Daniel Lawton · Executive Officer, Director
  • Klaus Veitinger · Executive Officer, Director
  • Tom Beck · Executive Officer, Director
  • Patrick Schwarz-Schuette · Director
  • Stacey Seltzer · Director
  • Steve Squinto · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds are used for research and development and general corporate purposes. The executive officers and certain directors will receive compensation from the Issuer's investment proceeds.”

Signed by Daniel Lawton, President. Newest notice filed Sep 25, 2017. Read the notice at the SEC.

equitySEC
Sep 2016$9 MNo. 2$2 to $10 million

Promentis Pharmaceuticals, Inc.: Raise no. 2, Sep 2016

Investors in this round

8 investors had bought by the notice of Oct 5, 2016: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chad Beyer · Executive Officer
  • Daniel Lawton · Executive Officer, Director
  • Klaus Veitinger · Executive Officer, Director
  • Tom Beck · Executive Officer, Director
  • Patrick Schwarz-Schuette · Director
  • Stacey Seltzer · Director
  • Steve Squinto · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds are used for research and development and general corporate purposes. The executive officers and certain directors will receive compensation from the Issuer's investment proceeds.”

Signed by Daniel Lawton, President. Newest notice filed Oct 5, 2016. Read the notice at the SEC.

equitySEC
Aug 2009$2 MNo. 1Under $2 million

Promentis Pharmaceuticals, Inc.: Raise no. 1, Aug 2009

Investors in this round

5 investors had bought by the notice of Aug 31, 2009: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
  • 46
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$50,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Lawton · Executive Officer, Director
  • David A Baker, PhD · Director
  • Ed Barthell · Director
  • Klaus Veitinger · Director
  • Patrick Schwarz-Schuette · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Expense reimbursement for out of pocket expenses.”

Signed by Daniel G. Lawton, President and Chief Executive Officer. Newest notice filed Aug 31, 2009 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Promentis Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2019).

    SEC Form D · Dec 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2019

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Promentis Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Promentis Pharmaceuticals, Inc.
NameRoleNamed in
Chad BeyerExecutive officerDec 2019
Daniel LawtonExecutive officerDec 2019
Klaus VeitingerExecutive officerSep 2017
Tom BeckExecutive officerSep 2017
Daniel LawtonDirectorDec 2019
Klaus VeitingerDirectorDec 2019
Patrick Schwarz-SchuetteDirectorDec 2019
Stacey SeltzerDirectorDec 2019
Steve SquintoDirectorDec 2019
Thomas BeckDirectorDec 2019
Tom BeckDirectorSep 2017
David A Baker, PhDDirectorAug 2009
Ed BarthellDirectorAug 2009

About

Company in Milwaukee, United States.